Compare HRTG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | COLL |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.9M | 752.3M |
| IPO Year | 2014 | 2015 |
| Metric | HRTG | COLL |
|---|---|---|
| Price | $34.00 | $25.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $42.50 | ★ $44.88 |
| AVG Volume (30 Days) | 202.6K | ★ 633.8K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.94 | 0.64 |
| Revenue | ★ $847,330,000.00 | $780,567,000.00 |
| Revenue This Year | $1.63 | $6.73 |
| Revenue Next Year | $3.02 | $1.37 |
| P/E Ratio | ★ $6.81 | $38.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.48 | $21.43 |
| 52 Week High | $37.87 | $50.79 |
| Indicator | HRTG | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 61.50 |
| Support Level | $32.83 | $21.67 |
| Resistance Level | $35.75 | $26.39 |
| Average True Range (ATR) | 1.32 | 0.84 |
| MACD | -0.32 | 0.17 |
| Stochastic Oscillator | 28.69 | 61.34 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.